Table 2.
Inclusion criteria |
---|
Papers reporting on HRQoL from the perspective of the patient and excluding clinician rated measures |
Papers including patients diagnosed with GC (on or off treatment) and within or equal to 1 year of treatment. This includes patients with Upper gastro-intestinal tumours (stomach only) or patients with cancer within 2 cm of the esophagogastric junction. This will not include patients with upper gastro-intestinal tumours if they are oesophageal, or duodenum tumours or patients with oesophageal cancer not within 2 cm of the EGJC or where location is not specified, or patients with concurrent disease |
This will include studies on patients with different diagnoses alongside GC, as long as HRQoL data for people with GC are reported separately |
Papers reporting studies on adult patients aged 18 years and above diagnosed with gastric/stomach cancer |
Papers reporting studies involving patients from all countries including East Asia (Japan, South Korea, North Korea China, Taiwan, Mongolia, and Macau) |
Papers published between January 2001 and January 2021 |
Papers published in English Language |
Studies including the following designs: 1. Randomised controlled trials |
2. Trials of quasi-experimental design (observational, case–control) |
3. Qualitative studies |
4. Mixed methods |
Conference proceedings, theses, protocols, cost-effectiveness studies, studies reporting on animals and those not including primary data (e.g., reviews, case studies, expert opinion, theoretical papers, policy documents, guidelines, consensus, letters, editorials) will be excluded |
Relevant grey literature from searches |